In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator Timothy A. Yap, Ph.D., associate professor of Investigational Cancer Therapeutics, today presented initial data from the trial at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics...
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center today named Caroline Chung, M.D., associate professor of Radiation Oncology and Diagnostic Radiology, the new vice president and chief data officer (CDO), effective Oct. 1.
As the institution’s first-ever CDO, Chung will be responsible for shaping MD Anderson’s data strategy and leading its implementation from an operational and cultural perspective. She will oversee the Data...
The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation today announced the launch of a collaboration designed...
The University of Texas MD Anderson Cancer Center and Siemens Healthineers today announced the collaborative development of a global education...
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development...
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer...
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...